<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2022-8-103-106</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-2616</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭСТЕТИЧЕСКАЯ МЕДИЦИНА</subject></subj-group></article-categories><title-group><article-title>Ботулинотерапия в лечении больных розацеа</article-title><trans-title-group xml:lang="en"><trans-title>Botulinum therapy in treatment of patients with rosacea</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1446-4450</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вербовая</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Verbovaya</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Вербовая Елена Дмитриевна, ординатор I года кафедрыдерматовенерологии и косметологии</p></bio><bio xml:lang="en"><p> Verbovaya Elena D., 1st year resident of Dept of Dermatovenereology and Cosmetology </p></bio><email xlink:type="simple">verbovaya.lena@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3429-6693</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Родина</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Rodina</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Родина Александра Леонидовна, ординатор II года кафедрыдерматовенерологии и косметологии</p></bio><bio xml:lang="en"><p> Rodina Alexandra L., 2nd year resident of Dept of Dermatovenereology and Cosmetology </p></bio><email xlink:type="simple">al.rodina@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>18</day><month>05</month><year>2022</year></pub-date><volume>0</volume><issue>8</issue><issue-title>Дерматология (1)</issue-title><fpage>103</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вербовая Е.Д., Родина А.Л., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Вербовая Е.Д., Родина А.Л.</copyright-holder><copyright-holder xml:lang="en">Verbovaya E.D., Rodina A.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/2616">https://www.med-alphabet.com/jour/article/view/2616</self-uri><abstract><p>В статье рассмотрены эпидемиология, патоморфологическая картина, триггерные факторы развития розацеа, особенности ботулинотерапии при этом заболевании. Представлены клинические примеры.</p><sec><title>Цель статьи</title><p>Цель статьи. Рассмотреть патогенез розацеа, исследовать механизм с помощью которого ботулинический токсин улучшает состояние кожи при розацеа.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В статье представлены клинические примеры применения ботулинотерапии в лечении больных розацеа.</p></sec><sec><title>Результаты</title><p>Результаты. Результаты клинических примеров показывают, что внутрикожные инъекции ботулотоксина безопасны и эффективны и приводят к уменьшению эритемы при розацеа.</p></sec><sec><title>Выводы</title><p>Выводы. Ботулинотерапия может выступать альтернативным методом терапии у пациентов с рефрактерной к стандартным методам лечения стойкой эритемой. Эффект после ботулинотерапии сохраняется в течении 2–4 месяцев. Необходимы дальнейшие исследования эффективности и безопасности данной методики у пациентов с различными подтипами розацеа, в том числе при сочетании подтипов.</p></sec></abstract><trans-abstract xml:lang="en"><p>The article deals epidemiology, pathomorphological picture, trigger factors of development, peculiarities of treatment with the use of botulinum therapy for rosacea. A clinical case is presented.</p><sec><title>Purpose of the article</title><p>Purpose of the article. Consider the pathogenesis of rosacea, investigate the molecular mechanism by which botulinum toxin improves the condition in rosacea.</p></sec><sec><title>Material and methods</title><p>Material and methods. The article presents clinical examples of botulinum therapy in the treatment of patients with rosacea. The epidemiology, pathomorphological picture, developmental trigger factors, diagnostic features and approaches to the treatment of rosacea in modern conditions are considered.</p></sec><sec><title>Results</title><p>Results. Case study results show that intradermal botulinum toxin injections are safe and effective in reducing erythema and ﬂushing in rosacea.</p></sec><sec><title>Conclusions</title><p>Conclusions. Botulinum therapy – may be an alternative therapy for patients with refractory to standard treatment of persistent erythema. The effect after botulinum therapy lasts for 2–4 months. Further research is needed on the effcacy and safety of this technique in patients with different subtypes of rosacea, including those with a combination of subtypes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>розацеа</kwd><kwd>ботулинотерапия</kwd><kwd>ботулинический токсин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rosacea</kwd><kwd>botox</kwd><kwd>mechanism of action</kwd><kwd>botulinum therapy</kwd><kwd>botulinum toxin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гоукроджер Дэвид Дж., Арден-Джонс Майкл Р. Дерматология. Иллюстрированное руководство. Москва: Издательство ГЭОТАР-Медиа, 2021. С. 320.</mixed-citation><mixed-citation xml:lang="en">Goukroger David J., Arden-Jones Michael R. Dermatology. Illustrated guide. Moscow: GEOTAR-Media Publishing House, 2021. P. 320.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Egorova O.A. Use of botulinum toxin type A in patients with erythematous-telangiectatic rosacea. Medical alphabet. 2019; 2 (26): 100–104. (In Russ.) https://doi.org/10.33667/2078–5631–2019–2–26(401)-100–104</mixed-citation><mixed-citation xml:lang="en">Egorova O.A. Use of botulinum toxin type A in patients with erythematous-telangiectatic rosacea. Medical alphabet. 2019; 2 (26): 100–104. (In Russ.) https://doi.org/10.33667/2078–5631–2019–2–26(401)-100–104</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кубанова Н.Е., Мантурова Ю.А., Галлямова. Руководство по косметологии. Москва: Издательство АНО Изд. дом «Науч. обозрение», 2020. С. 728.</mixed-citation><mixed-citation xml:lang="en">Kubanova N.E., Manturova Yu.A., Galliamova. Guide to cosmetology. Moscow: ANO Publishing House ‘Scientifc review’, 2020, p. 728.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Круглова Л.С., Стенько А.Г., Грязева Н.В. Акне и розацеа. Клинические проявления, диагностика и лечение. Москва: Издательство ГЭОТАР-Медиа, 2021. С. 208.</mixed-citation><mixed-citation xml:lang="en">Kruglova L.S., Stenko A.G., Gryazeva N.V. Acne and rosacea. Clinical manifestations, diagnosis and treatment. Moscow: GEOTAR-Media Publishing House, 2021. P. 208.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Матушевская Е.В. Акне и розацеа. Матушевская Е.В., Свирщевская Е.В. Акне и розацеа. Москва: Издательство ГЭОТАР-Медиа, 2020. С. 120. (Серия «Библиотека врача-специалиста»). Matushevskaya E. V. Acne and rosacea. Matushevskaya E. V., Svirshchevskaya E. V. Acne and rosacea. Moscow: GEOTAR-Media Publishing House, 2020. P. 120. (Series ‘Library of a specialist doctor’).</mixed-citation><mixed-citation xml:lang="en">Матушевская Е.В. Акне и розацеа. Матушевская Е.В., Свирщевская Е.В. Акне и розацеа. Москва: Издательство ГЭОТАР-Медиа, 2020. С. 120. (Серия «Библиотека врача-специалиста»). Matushevskaya E. V. Acne and rosacea. Matushevskaya E. V., Svirshchevskaya E. V. Acne and rosacea. Moscow: GEOTAR-Media Publishing House, 2020.  P. 120. (Series ‘Library of a specialist doctor’).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Carruthers J., Fournier N., Kerscher M., Ruiz-Avila J. Trindade de Almeida A. R., Kaeuper G. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg. 2018; 39 (3 Pt 2): 510–525.</mixed-citation><mixed-citation xml:lang="en">Carruthers J., Fournier N., Kerscher M., Ruiz-Avila J. Trindade de Almeida A. R.,  Kaeuper G. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg. 2018; 39 (3 Pt 2): 510–525.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang D.Z., Liu X.Y., Xiao W.L., Xu Y.X. Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS One. 2016; 11 (3): e0151627.</mixed-citation><mixed-citation xml:lang="en">Zhang D.Z., Liu X.Y., Xiao W.L., Xu Y.X. Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS One. 2016; 11 (3): e0151627.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Choi J.E., Werbel T., Wang Z., Wu C.C., Yaksh T.L., Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inﬂammation. J Dermatol Sci 2019; 93 (1): 58–64.</mixed-citation><mixed-citation xml:lang="en">Choi J.E., Werbel T., Wang Z., Wu C.C., Yaksh T.L., Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inﬂammation. J Dermatol Sci 2019; 93 (1): 58–64.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Capek P., Dickerson T.J. Sensing the deadliest toxin: technologies for botulinum neurotoxin detection. Toxins (Basel) 2010; 2 (1): 24–53.</mixed-citation><mixed-citation xml:lang="en">Capek P., Dickerson T.J. Sensing the deadliest toxin: technologies for botulinum neurotoxin detection. Toxins (Basel) 2010; 2 (1): 24–53.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
